Lipocine (LPCN) Competitors

Acumen Pharmaceuticals (NASDAQ:ABOS) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Do insiders & institutionals believe in ABOS or LPCN?

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is ABOS or LPCN more profitable?

Lipocine's return on equity of -19.17% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%
Lipocine	N/A	-19.17%	-17.60%

Does the MarketBeat Community favor ABOS or LPCN?

Lipocine received 320 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Acumen Pharmaceuticals an outperform vote while only 67.25% of users gave Lipocine an outperform vote.

Company	Underperform	Outperform
Acumen Pharmaceuticals	Outperform Votes 27 72.97%	Underperform Votes 10 27.03%
Lipocine	Outperform Votes 347 67.25%	Underperform Votes 169 32.75%

Which has more volatility & risk, ABOS or LPCN?

Acumen Pharmaceuticals has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Does the media prefer ABOS or LPCN?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.68 beat Lipocine's score of 1.32 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, ABOS or LPCN?

Lipocine has higher revenue and earnings than Acumen Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$52.37M	-$1.71	-0.61
Lipocine	$11.20M	1.46	-$16.35M	-$0.01	-305.00

Do analysts recommend ABOS or LPCN?

Acumen Pharmaceuticals presently has a consensus target price of $7.33, indicating a potential upside of 598.41%. Lipocine has a consensus target price of $10.00, indicating a potential upside of 227.87%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Lipocine	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Acumen Pharmaceuticals beats Lipocine on 9 of the 16 factors compared between the two stocks.